|
FOI
|
FOI+/MRI+
|
FOI−/MRI-
|
Sens.
|
Spec.
|
PPV
|
NPV
|
AUC
|
PA
|
|---|
|
PVM
|
698/1456
|
1180/1635
|
0.48
|
0.72
|
0.61
|
0.61
|
0.61
|
61
|
|
Phase 1
|
22/1442
|
1621/1635
|
0.02
|
0.99
|
0.61
|
0.53
|
0.50
|
53
|
|
Phase 2
|
814/1408
|
984/1585
|
0.58
|
0.62
|
0.58
|
0.62
|
0.60
|
60
|
|
Phase 3
|
332/1407
|
1408/1572
|
0.24
|
0.90
|
0.67
|
0.57
|
0.57
|
58
|
|
FOI
|
FOI+/GS+
|
FOI−/GS−
|
Sens.
|
Spec.
|
PPV
|
NPV
|
AUC
|
PA
|
|
PVM
|
407/688
|
3510/5473
|
0.59
|
0.64
|
0.17
|
0.93
|
0.62
|
64
|
|
Phase 1
|
16/680
|
5412/5454
|
0.02
|
0.99
|
0.28
|
0.89
|
0.51
|
88
|
|
Phase 2
|
461/667
|
2977/5299
|
0.69
|
0.56
|
0.17
|
0.94
|
0.63
|
58
|
|
Phase 3
|
152/664
|
4545/5273
|
0.23
|
0.86
|
0.17
|
0.90
|
0.56
|
79
|
- FOI fluorescence optical imaging, PVM FOI Prima Vista Mode, Phase 1 FOI phase 1, Phase 2 FOI phase 2, Phase 3 FOI phase 3, MRI magnetic resonance imaging, GS gray-scale ultrasound, Sens. sensitivity, Spec. specificity, PPV positive predictive value, NPV negative predictive value, PA percent agreement, AUC area under the curve
